MICHAEL BUTZEN: Open Payments
NPI 1760036776 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$865 in 39 payments from 19 companies in 2025. Trend: 2023 $2,283 · 2024 $991 · 2025 $865
Food & beverage: $865
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 8 | $174 |
| Merck Sharp & Dohme LLC | 4 | $104 |
| ViiV Healthcare Company | 4 | $81 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| Gilead Sciences, Inc. | 2 | $61 |
| Melinta Therapeutics, LLC | 3 | $60 |
| Insmed, Inc. | 2 | $41 |
| Cumberland Pharmaceuticals, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $31 |
| ABBVIE INC. | 1 | $30 |
Products named: NUZYRA, GEMTESA, Rezzayo, PIFELTRO, ZERBAXA, Arikayce, VIBATIV, Xtandi.
Industry payments across GA — which companies pay providers there.
